ArticleScientific reports2025
T lymphocyte subsets and mitochondrial index predict outcomes in advanced non small cell lung cancer therapy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Mitochondrial fitness in circulating T cells predicts neoadjuvant therapy response in locally advanced colorectal cancer.Gastroenterology report · 2026Article
- A novel study to calculate immune-aging from peripheral blood T lymphocyte subsets and their mitochondrial parameters in healthy Chinese subjects.Frontiers in immunology · 2026Article
- Peripheral blood T-lymphocyte subsets provide prediction of early postoperative recurrence in elderly patients with lung cancer: model development and external validation.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Currently, accessible objective indicators for predicting the prognosis and treatment outcomes of non-small cell lung cancer (NSCLC) are lacking. This study investigates the potential of T lymphocyte subsets and mitochondrial biomarkers as predictors of metastasis and evaluators of therapy response in advanced NSCLC. We analyzed clinical data from 24 advanced NSCLC patients, including T-cell counts and mitochondrial mass (MM)/membrane potential (MMP) measurements. Group comparisons used parametric t-tests and non-parametric Mann-Whitney U tests, with False Discovery Rate (FDR) correction for multiple comparisons. Predictive performance was evaluated via receiver operating characteristic (ROC) curves (area under curve, AUC). CD8 + T cells with low mitochondrial membrane potential (MMP-Low) and CD8 + T-cell mitochondrial mass (MM) showed promising potential in predicting metastasis (AUC = 0.85 and 0.87). Three T-cell biomarkers correlated with therapeutic outcomes (p < 0.05): PD-1 + CD8 + T-cell percentage, MMP-Low CD8 + T-cell proportion, CD8 + T-cell MM levels. Our exploratory findings suggest that T lymphocyte subsets and mitochondrial indices show potential as biomarkers to evaluate therapy response and predict metastasis risk in advanced NSCLC, which may facilitate individualized treatment and timely regimen adjustment for patients pending further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.